- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02496156
Shared Medical Decision Making in Pediatric Diabetes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Abstract (modified after achievement of Aims 1 and 2):
Treatment adherence in type 1 diabetes (T1D) tends to decline among adolescents, increasing risks of acute and chronic complications, excess health care use, poorer quality of life, and T1D-related family conflict. Poor adherence is associated with psychiatric and family dysfunction and often persists into early adulthood. Therapeutic advances such as continuous subcutaneous insulin infusion (CSII or "insulin pump") and continuous glucose monitoring (CGM) could improve metabolic control and quality of life.
But, teens often do not benefit fully from such advances. Many studies of adults show that patient-centered communication styles predict more favorable clinical outcomes. Shared medical decision making (SMDM) interventions have improved outcomes among adults with diabetes and other conditions. Research in pediatrics has also shown that patient-centered and family-centered communication styles predict favorable outcomes, but most of this research is in primary care and has not studied youth with chronic conditions. Since there have been no controlled trials of SMDM with chronically ill youths, we propose a randomized controlled trial of an SMDM intervention compared with Usual Clinical Practice (UCP). Qualitative interviews of youths and parents who have previously faced these decisions and reliance on expert consultants, pediatric endocrinologists and diabetes educators have preceded this trial and provided valued input for refining the planned intervention and adapting the structured SMDM format for pediatrics. Now, we will recruit and randomize 166 11-<17 year old youth with T1D who are candidates for CSII or CGM (and a parent/caregiver) at all Nemours sites. The SMDM intervention will be delivered via a web-based platform, facilitated by Diabetes Educators (DEs) at each site in a standardized, yet individually tailored format. SMDM will employ multimedia "decision aids" prepared with the award-winning Nemours Center for Children's Health Media and the "e-city interactive" web design firm in Philadelphia in accord with pertinent international standards. SMDM will also include individualized assistance from the DE in assuring that each youth's and parent's preferences, values and cultural beliefs are carefully addressed and communicated to the attending endocrinologist. After a baseline evaluation and randomization to SMDM or UCP, effects on the primary outcome (treatment adherence; device utilization) and secondary outcomes (glycemic control, treatment alliance, decision conflict and regret, treatment satisfaction, diabetes-related distress and self-efficacy) will be measured over 1 year. Mixed effects modeling will be the primary analytic technique for evaluating effects on primary/secondary outcomes, examining selected variables as moderators and mediators of treatment effects, and assessing whether such effects are comparable for the two medical decisions of interest. The results will verify whether SMDM in this context enhances treatment adherence, device use and parent/patient-reported outcomes in youth with T1D.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Nemours Children's Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Type 1 diabetes for 1 year or more
- At least 2 diabetes clinic visits at the enrolling site in the prior year
- Considered by treating endocrinologist to be a candidate for insulin pump or continuous glucose monitor
- Intent to continue care at Nemours for 1 year
- Internet access at home, school, work or relative's home
Exclusion Criteria:
- Open case with child protection agency
- Unable to read and speak English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Usual Clinical Practice (UCP)
UCP participants will receive the same clinical and educational management for candidates for insulin pump or continuous glucose monitoring that is received by similar patients who are not enrolled in this study.
The respective endocrinology practices at the enrolling sites all strive to meet or exceed the current American Diabetes Association Standards for Clinical Practice in the management of type 1 diabetes in this population.
Thorough patient education is the cornerstone of that care, especially regarding the incorporation of insulin pumps and continuous glucose monitors into the treatment regimen for a given patient.
|
Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
|
Experimental: Shared Medical Decision Making (SMDM)
Participants randomized to SMDM receive all components of UCP supplemented with access to the decision aid website pertinent to the medical decision of interest (pump or CGM).
Adolescents and parents will receive password-protected, secure access to the decision for their use until a decision is reached.
The platform will then generate a summary report that the adolescent and parent will discuss with a diabetes nurse and then a visit with the treating endocrinologist will be scheduled to conclude the SMDM intervention for that adolescent and parent.
|
Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Continuous Glucose Monitor Use Profile or Insulin Pump Use Profile
Time Frame: Measure was collected at each study visit after the participant actually obtained a CGM or Insulin Pump
|
Adolescent and Parent report regarding degree to which use of the device of interest has become an integral part of the adolescent's daily diabetes self management.
Scores may range from 10 to 50, with higher scores reflecting more frequent and meticulous use of the diabetes device of interest.
|
Measure was collected at each study visit after the participant actually obtained a CGM or Insulin Pump
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycated Hemoglobin (Hemoglobin A1C)
Time Frame: Every 3 months for for 1 year
|
Glycated hemoglobin (Hemoglobin A1C) expressed as the percentage of hemoglobin molecules that are bound to glucose.
Normal range is approximately 4.5% to 6.5%, Higher values indicate a higher blood glucose concentration over the preceding 2-3 months.
|
Every 3 months for for 1 year
|
Decision Regret Scale
Time Frame: Obtained at Visits 3 and 5 only
|
Questionnaire measuring decision making regret.
Reflecting on a specific decision (accept or decline opportunity to use CGM or insulin pump), higher score reflect a greater degree of regret regarding the decision that was made.
Scores may range from 5 to 20.
|
Obtained at Visits 3 and 5 only
|
Knowledge of Insulin Pump or Continuous Glucose Monitor
Time Frame: Baseline and 3 months later
|
Brief test of parent and adolescent knowledge about the pertinent device and its use.
Higher scores reflect more precise knowledge about the diabetes device of interest.
Scores may range from 1 to 5.
|
Baseline and 3 months later
|
Diabetes Self Management Profile Self Report Form
Time Frame: Visits 1, 3 and 5
|
Composite measure of diabetes treatment adherence consisting of combined scores based on reports of parents and adolescents.
Higher scores reflect more meticulous adherence to recommended diabetes self management behaviors.
Scores may range from 0 to 86.
|
Visits 1, 3 and 5
|
SURE Test
Time Frame: Measured at Follow-up Visits 3 and 5 only
|
4-item questionnaire that measures patients' confidence in a health care decision that has been made.
Scores may range from 0-4 with higher scores reflecting greater confidence in the decision made regarding insulin pump or CGM.
|
Measured at Follow-up Visits 3 and 5 only
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tim Wysocki, PhD, Nemours Biomedical Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCORI 805
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on Usual Clinical Practice
-
McMaster UniversityUniversity of British Columbia; University of Manchester; Merck Canada Inc.Recruiting
-
Consorci Sanitari de l'Alt Penedès i GarrafCompletedFull-term Newborn BabiesSpain
-
University of MalagaKing's College LondonWithdrawnMild Cognitive ImpairmentSpain
-
University of MalagaKing's College LondonRecruiting
-
Hospital San Carlos, MadridNot yet recruitingKidney Transplant; ComplicationsSpain
-
Institut Investigacio Sanitaria Pere VirgiliUniversity Rovira i Virgili; Hospital Universitari Joan XXIII de Tarragona.; Hospital...Active, not recruitingMicrobial ColonizationSpain
-
Gerencia de Atención Primaria, MadridFondo de Investigacion Sanitaria; Instituto de Salud Carlos IIICompletedPerimenopausal WomenSpain
-
Azienda Ospedaliero Universitaria Maggiore della...Not yet recruiting
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Catalan Society of Family Medicine; Comité Nacional Prevención Tabaquismo; Unitat...UnknownTobacco Smoke PollutionSpain
-
University of North Carolina, Chapel HillCompletedPelvic Organ ProlapseUnited States